Search

Search Constraints

You searched for: Author/Creator Nussenzveig, Roberto

Search Results

2. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer. (2020)

3. Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. Issue 2 (11th August 2020)

5. Modulation of Premetastatic Niche by the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Localized High‐Risk Prostate Cancer Followed by Radical Prostatectomy: A Phase II Randomized Trial. (1st November 2018)

6. Multi-institutional Analysis of the Clinical and Genomic Characteristics of Black Patients with Metastatic Hormone-Sensitive Prostate Cancer. (24th February 2022)

7. Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. (23rd September 2021)

8. Radium‐223 plus Enzalutamide Versus Enzalutamide in Metastatic Castration‐Refractory Prostate Cancer: Final Safety and Efficacy Results. (23rd September 2021)

9. Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair‐Deficient Prostate Cancer. (3rd December 2020)